Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Johnson and Johnson...

    Johnson and Johnson Faulty Hip Implants: Ministry asks States to determine Compensation

    Written by Ruby Khatun Khatun Published On 2018-08-25T17:44:13+05:30  |  Updated On 25 Aug 2018 5:44 PM IST
    Johnson and Johnson Faulty Hip Implants: Ministry asks States to determine Compensation

    The panel set up by the health ministry had recommended a base amount of Rs 20 lakh as compensation to each patient who had received the faulty hip implant


    New Delhi: Soon Indian patients who suffered from adverse effects with the "faulty" hip implants imported and sold by Johnson and Johnson in India before 2010 will be getting relief and compensation.


    Medical Dialogues team had earlier reported that Compensation had been recommended by a panel set up by the health ministry, in order to provide relief to patients who received faulty hip implants from Johnson and Johnson seven years ago.


    The panel, led by Dr Arun Kumar Agarwal, former dean of Maulana Azad Medical College, suggested a base amount of Rs 20 lakh each for all the patients who were received defective implants and had to be replaced with corrective surgery.


    Read also: First: Health Ministry Panel wants JnJ to pay at least Rs 20 lakh to patients for faulty implants

    The genesis of the case goes back to the year 2010 when a hip replacement device namely DePuy ASR was recalled over reports of metal poisoning and high failures due to the presence of toxic chromium, cobalt and a design flaw that filtered into the body, causing danger to lives. It was sold in India by DePuy International, a subsidiary of J&J.


    4,500 patients in India had received this implant, and J&J is said to have reported over 100 serious adverse events to the Central Drugs Standard Control Organisation (CDSCO) between 2014 and 2017.


    Business Standard reports that the first complaint was lodged in Maharashtra in 2011. The state’s food and drug administration (FDA) took it up actively. An FIR was filed in 2014, naming DePuy Synthes, a subsidiary of Johnson & Johnson. But, the authorities could not push for compensation. The case went to the Bombay High Court. The court advised the FDA to continue with the inquiry, but nothing happened.


    In February 2016, the panel was formed by the government to investigate the case as India has no specific legal provisions to pay compensation in such cases.


    Following the recommendation of the expert committee to compensate the patients who had been administered with faulty hip implants, the health ministry is now reaching out to the states and asking them to form state-level committees that will evaluate claims made by patients with regard to disability and suffering caused by the implant.


    It has been reported that the complaints will be process within two months after examining all physical and clinical findings to understand the extent of disability the patient has suffered due to the implant by the state committees and the report will be submitted to a central committee set up for this purpose that will examine the findings and decide how much patients would be compensated before directing J&J to pay the patients.


    In order to track any patient suffering from the adverse reactions of these implants, the state committees have to reach out to hospitals as the government does not expect every affected patient to come forward on their own.

    R K Vats, additional secretary in the health ministry told Mint, “The company is at fault and there is no doubt about it. They will have to pay compensation to those who suffered due to their faulty implant.”


    The company is yet to receive the expert committee's report and said it would be inappropriate for it to comment on the developments.


    A company spokesperson told ET, “We would like to reiterate that we have furnished full facts and data available with us to the expert committee. It is important to note that a voluntary recall doesn’t imply that the product is faulty nor does it imply that every patient who has received an ASR hip implant will necessarily have to undergo revision surgery. DePuy has maintained transparency and openness.”

    adverse effectsCDSCOCentral Drugs Standard Control Organisationclinical findingscompensationDePuy ASRDePuy InternationalDr Arun Kumar Agarwalexpert committeeFaulty hip implantsHealth Ministryhip implanthip implantsJnJJohnson and JohnsonMaulana Azad Medical CollegeR K Vats
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok